Bristol Myers: positive opinion from CHMP for Opdivo

(CercleFinance.com) - Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable metastatic colorectal cancer or MSI-H/dMMR.


This opinion is based on a study showing a 79% reduction in the risk of progression or death compared to chemotherapy.

According to Dana Walker, Vice President at Bristol Myers Squibb, this combination therapy could offer 'a transformative benefit'.

The final decision now rests with the European Commission.


Copyright (c) 2024 CercleFinance.com. All rights reserved.